ConductScience.org, home

Comparison · NCT04068792-sae

JNJ-53718678 vs Placebo: serious adverse events

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. JNJ-53718678 vs Placebo: serious adverse events. Trial comparisons, record NCT04068792-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04068792-sae

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.09090.01620.377wilson
Risk in group 20.09090.01620.377wilson
Risk difference, group 1 minus group 20-0.2960.296newcombe hybrid score
Risk ratio, group 1 over group 210.071214.1log
Odds ratio, group 1 over group 210.054618.3log
Number needed to harmfrom the risk difference intervalthe two groups' risks are equal

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1JNJ-53718678
As per original dosing, participants were randomized to receive JNJ-53718678 (for Age Group 1 \[\>= 28 days and \< 3 months\]: 5 milligrams/kilogram \[mg/kg\]; for Age Group 2 \[\>=3 and \<6 months\]: 6 mg/kg and for Age Group 3 \[\>=6 months\]: 9 mg/kg) orally qd for 7 days. After Protocol amendment 2, participants were randomized to receive JNJ-53718678 (for Age Group 1: 2.5 mg/kg; for Age Group 2: 3 mg/kg and for Age Group 3: 4.5 mg/kg) orally bid for 7 days
111EG001
Group 2Placebo
As per original dosing, participants were randomized to receive JNJ-53718678 matching placebo (for Age Group 1 \[greater than or equal to {\>=} 28 days and less than {\<} 3 months\], for Age Group 2 \[\>=3 and \<6 months\], and for Age Group 3 \[\>=6 months\]) orally once daily (qd) for 7 days. After Protocol amendment 2, participants were randomized to receive JNJ-53718678 matching placebo (for Age Groups 1, 2, and 3) orally twice daily (bid) for 7 days.
111EG000

Harm

What it counts
Total, serious adverse events
Time frame
Up to Day 31

Source ClinicalTrials.gov

Trial

Title
A Two-Part Infant Study for Early Diagnosis of Respiratory Syncytial Virus (RSV) and Evaluation of JNJ-53718678 in RSV Acute Respiratory Tract Disease
NCT number
NCT04068792
Phases
PHASE2
Conditions
Respiratory Syncytial Viruses
Interventions
RSV Mobile Application, Placebo, JNJ-53718678 2.5 mg/kg, JNJ-53718678 3 mg/kg, JNJ-53718678 4.5 mg/kg
Lead sponsor
Janssen Research & Development, LLC
Results first posted
2022-06-08

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT04068792-sae